Zydus Lifesciences receives tentative FDA approval for Azilsartan Medoxomil Tablets
Zydus Lifesciences Limited has achieved a significant milestone with the tentative approval from the United States Food and Drug Administration (USFDA) to market Azilsartan Medoxomil Tablets, in 40 mg and 80 mg dosages. This medication is an angiotensin II receptor blocker (ARB) specifically used for the treatment of hypertension to lower blood pressure, thereby reducing the risk of cardiovascular events such as strokes and myocardial infarctions.
The approval marks a crucial step for Zydus in expanding its portfolio in the highly competitive U.S. market. Azilsartan Medoxomil Tablets have reported annual sales of approximately USD 89 million in the United States, according to IQVIA MAT as of March 24. This approval will allow Zydus to prepare for a full-scale launch, pending the final approval once patent exclusivities have expired.
Manufactured in the group’s cutting-edge formulation facility located in Ahmedabad SEZ – II, India, Azilsartan Medoxomil Tablets can be prescribed alone or in combination with other antihypertensive agents. This flexibility makes it a valuable option for healthcare providers managing patients with varying levels of hypertension.
Zydus has a strong track record in the pharmaceutical industry, with a total of 398 approvals and over 460 Abbreviated New Drug Applications (ANDAs) filed since the commencement of its filing process in FY 2003-04. The company’s commitment to high-quality manufacturing and compliance with stringent global standards is evident in its state-of-the-art facilities and robust product pipeline.
Dr. Sharvil Patel, CEO of Zydus Group, commented on the approval: “Receiving tentative approval from the USFDA for Azilsartan Medoxomil Tablets underscores our commitment to providing high-quality and affordable healthcare solutions globally. We are proud of our team’s efforts and look forward to bringing this important medication to market, enhancing our offerings in the cardiovascular drugs segment.”